The antibiotic-eluting matrix met performance endpoints in a rabbit study, with no viable MRSA or E. coli bacteria recovered from the matrix or surrounding tissue.

Elutia intends to submit NXT-41x, its antibiotic-eluting biologic matrix, to the US Food and Drug Administration in the fourth quarter of 2026. The company announced the plan with its third-quarter financial results.

NXT-41x is a biologic matrix with an antibiotic coating on one side only. Elutia is developing it to deliver localized antibiotic therapy directly to the surgical site in reconstructive surgery. The company anticipates clearance in the first half of 2027.

“After adding $26 million without an equity offering, we believe we have the technology, the team, and the capital to advance NXT-41x toward anticipated clearance,” says Randy Mills, CEO of Elutia, in a release.

Rabbit Study Results

Elutia reports that a GLP rabbit study of infection met its predetermined performance endpoints. No viable bacteria were recovered from the matrix or the surrounding tissue after an 8-log challenge with methicillin-resistant Staphylococcus aureus or a 6-log E. coli challenge. In the study, the bacterial challenge was applied directly to the uncoated side, which the company describes as a worst-case test. By contrast, 100% of animals implanted with a matrix without antibiotics developed heavy colonization by the offending pathogens.

Methicillin-resistant Staphylococcus aureus is a highly drug-resistant form of the most common pathogen in breast surgery, according to the company.

At the American Society of Plastic Surgeons annual meeting, Plastic Surgery The Meeting 2026, held Oct. 15 to 18 in Houston, Elutia convened its NXT-41x Surgeon Steering Committee, which gave positive feedback on the product’s design and performance. According to Elutia, surgeons emphasized the importance of delivering antibiotics at the right place and time: “It’s about the drugs being in the right place at the right time.” For NXT-41x, Elutia says the right time means 30 days of coverage, through drain removal.

Infection Data From the Annual Meeting

Elutia said infection risk and prevention were discussed in all 11 breast research sessions, and 70 of 135 oral research presentations (51.9%) addressed infection. The company highlighted several independent studies presented at the meeting:

  • In 1,094 breasts undergoing immediate implant-based surgery, infection rates were 17.6% in women who did not receive chemotherapy before surgery and 23.0% in those who did (Lopes et al).
  • In 419 breasts treated with perioperative and postoperative antibiotics, the infection rate was 19.3% (Fernandez et al).
  • In a multicenter study of 4,647 patients at 170 health care organizations, extending antibiotics beyond 24 hours did not reduce infection at 30, 60, or 90 days (Yadav et al).

Elutia also said no commercially available product on the exhibit floor addressed infection in breast surgery.

Funding and Regulatory Timeline

Elutia says the $26 million came from three transactions completed over 51 days:

  • A $15 million loan facility with Avenue Capital Group, with $10 million funded at closing and $5 million available after NXT-41x clearance.
  • The sale of the SimpliDerm business to Cellution Biologics, which brought $8 million at closing and up to $3 million in contingent milestone payments over 18 months.
  • The release of $8 million held in escrow by Boston Scientific from the 2025 sale of the BioEnvelope business.

The company believes it has sufficient funding through NXT-41x clearance and launch. It expects a commercial soft launch in the second half of 2027 and a full launch in 2028.

Separately, the FDA review of NXT-41, the biologic surgical matrix without drug, remains on track, with a clearance decision anticipated this quarter, according to the company.

ID 405725948 © Tomert | Dreamstime.com